Basil Systems - Series A

$11.5M Raised

If you know life sciences, you know it’s less a “system” and more a spaghetti mess: regulatory knots, data deserts, clinical chaos. Founders usually patch the holes. Anthony C. decided to dynamite the foundation and rebuild it right. Basil Systems wasn’t born out of a brainstorm. It was born out of battle scars. After wins at Co3 Systems (sold to IBM), LOBBY7 Inc. (Nuance Communications), and SETEM (XMOS), Anthony saw the same movie replaying across pharma and MedTech: billion-dollar companies tripping over billion-dollar data problems. Basil is his answer: it doesn’t patch the cracks, it pours the new concrete.

Headquartered in Boston, Basil Systems launched in late 2019 with a mission: unify life sciences data so companies can stop drowning and start sprinting. Behind the curtain? An AI powered SaaS platform turning fragmented regulatory, clinical, and commercial intel into real-time, decision-ready firepower. BasilIntel isn’t another dashboard graveyard. It’s product lifecycle intelligence that works. It taps BasilLink, the largest indexed data set in life sciences, over 600M continuously updated records, and delivers insights through a full-text natural language interface, custom dashboards, and APIs slick enough to keep the Fortune 500 coming back for more.

And they're not just coming back, they're building on it. 4 of the 5 largest global medical device players are already locked in. So are pharma giants: Johnson & Johnson, Medtronic, and Baxter International Inc. When a case study shows a 93% jump in efficiency for EU MDR data gathering, you stop debating and start signing contracts. That’s not hype. That’s Basil.

Today, Basil Systems closed an $11.5M Series A funding, led by Golden Ventures with Hearst Ventures and Argosy Capital. Stack that on top of the $1.5M pre-seed (Mar 2021) and the $2.45M Seed VC-II (Oct 2023) rounds, and you’re staring at $15.45M raised, all laser-focused on scaling the platform that’s already flipping the tempo in life sciences. Shoutout to the quiet operators behind the scenes too: Christopher Neppes on marketing, Holli McMann handling CFO moves, and Cheryl Jessen, ex-Veeva, closing sales like a surgeon.

While valuations aren’t posted, whispers put Basil in the $10–$12.5M range back in 2021. Safe bet today’s number sings a different tune. Anthony isn’t playing for small wins. He’s stacking real bricks: expanding BasilIntel, leveling up AI / ML capabilities, deepening data set coverage, and onboarding CROs, regulatory bodies, and suppliers who’ve been stranded too long without a map.

Basil isn’t just selling software. They’re selling clarity in an industry built on confusion. In a space this loud, it’s rare to find a signal strong enough to cut through the static. Basil Systems didn’t just find the frequency. They became it.

Let’s connect and keep the momentum going across the tech ecosystem. Whether you’re a founder shaping the future, a leader driving change, a VC backing bold ideas, or an investor spotting the next big thing—together, we’re pushing boundaries. Proud to be building the future with you.

Let’s connect on LinkedIn and keep the conversation going.